Search

This consensus statement emerges from collaborative efforts among leading figures in critical care cardiology throughout the United States, who met to share their collective expertise on issues faced by those active in or pursuing contemporary critical care cardiology education. The panel applied fundamentals of adult education and curriculum design, reviewed requisite training necessary to provide high-quality care to critically ill patients with cardiac pathology, and devoted attention to a purposeful approach emphasizing diversity, equity, and inclusion in developing this nascent field. The resulting paper offers a comprehensive guide for current trainees, with insights about the present landscape of critical care cardiology while highlighting issues that need to be addressed for continued advancement. By delineating future directions with careful consideration and intentionality, this Expert Panel aims to facilitate the continued growth and maturation of critical care cardiology education and practice., Competing Interests: Funding Support and Author Disclosures Dr Elliott is the director of the Critical Care Cardiology Education Summit; has received grant funding from the American College of Cardiology; and has received educational honoraria from Zoll. Dr Bartos has received grant funding from the National Institutes of Health and the Leona M. and Harry B. Helmsley Charitable Trust. Dr Barnett has received research funding from Merck; and has received educational honorarium from Zoll. Drs Barnett, Alviar, Gage, Horowitz, and Katz are co-course directors of the NYU Langone Critical Care Cardiology Symposium, and the course has received industry support. Dr Roswell is the chair of the American College of Cardiology Critical Care Cardiology member section; and chair-elect of the American Board of Internal Medicine Board of Directors. Dr Alviar has received research funds from Baxter; and has served on the Speakers Bureau for Zoll and Abiomed. Drs Bennett and Jentzer are co-course directors of Heart to Heart: Advances in Cardiovascular Critical Care and Resuscitation. Dr Berg has received institutional grants to Brigham & Women’s Hospital from AstraZeneca and Pfizer; has received honoraria from the Medical Education Speakers Network and USV Private Limited; has received consulting fees from AstraZeneca, MobilityBio, Pfizer, and Youngene Therapeutics; and has served on clinical endpoint committees for studies sponsored by Beckman Coulter, Kowa Pharmaceuticals, and Tosoh Biosciences. Dr Bohula has received personal consulting fees from Novo Nordisk, Servier, and Esperion; has served on an events adjudication committee for Kowa; and has received research support from Regeneron. Drs Dahiya and Senman are the founders of www.ccc1stop.com and CCCEnthusiasts, LLC, which has received unrestricted funding support from Zoll and CardioNerds. Dr Gage has served on the Speakers Bureau (historic) and received honoraria from Abiomed; and has received educational honoraria from Zoll. Dr Higgins has received educational honoraria from Abbott. Dr Horowitz has received research funds from Inari and Penumbra. Dr Katz has served on the data safety monitoring board member for the Abiomed RECOVER IV trial; has received research support from Abbott Corporation; and has received speaker honoraria from Zoll. Dr Lee has received educational honoraria from Getinge. Dr Metkus has received consulting fees/honoraria from TelaDoc, BestDoctors, and Oakstone-EBIX; and receives textbook royalties from McGraw-Hill. Dr Solomon has received intramural research funds from the National Institutes of Health Clinical Center; and is the chair-elect of the American College of Cardiology Critical Care Cardiology member section. Dr Dudzinski is course director of 5C: Concepts in Contemporary Critical Care Cardiology, and this course has received educational grants from Abbott, Abiomed, and Zoll. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose., (Copyright © 2024 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)

Background: Heart failure is a leading cardiac morbidity prevalent across the globe. Its incidence is rising in direct proportion to increasing longevity all over the world. Demographic variables are important predictors of quality of life, morbidity, rehospitalization, and mortality due to systolic heart failure. The objective of our study was to assess the association of demographic variables with quality of life of systolic heart failure in patients presenting at Cardiology Out Patient Department, Hayatabad Medical Complex, Peshawar. Our study aims to inform policy making as it highlights some important demographics factors associated with quality of life. Methods: A cross sectional method was employed in the study to examine systolic heart failure and its prevalence across various demographic variables such as age, gender, marital status, activity, number of children, education, employment status, and BMI at cardiology OPD of a medical teaching institution in Peshawar. Consecutive sampling was used and data were collected through a structured questionnaire from 368 Systolic Heart Failure patients. Data were analyzed using SPSS version 22. Results: We had 368 participants, a majority of whom (n=290; 78.8%), were in NYHA class III. The rest (n=78; 21.2%) were in class IV. Minnesota Living with Heart Failure Questionnaire (MLHFQ) was used to categorize quality of life into 'Good', 'Moderate' and 'Poor'. Most participants were in the 'poor' category with MLHFQ scores >45 (n=193; 52.4%). Those who had scores between 25 -45 were categorized as 'moderate' (n=116; 31.5%), and participants who scored < 24 were categorized as having a 'good' quality of life (n=59; 16%). Reliability of tools was checked by Cronbach alpha which was 0.86 Conclusion: It was concluded that demographic variables have a significant effect on the overall morbidity of heart failure patients and heart failure related quality of life. [ABSTRACT FROM AUTHOR]

Background: Population-based secular trends in survival of patients with congestive heart failure (CHF) are central to public health research on the burden of the syndrome. Methods: Patients 35-79 years old with a CHF discharge code in 1995 or 2000 were identified in 22 Minneapolis-St. Paul hospitals. A sample of the records was abstracted (50% of 1995 records; 38% of 2000 records). A total of 2,257 patients in 1995 and 1,825 patients in 2000 were determined to have had a CHF-related hospitalization. Each patient was followed for one year to ascertain vital status. Results: The risk profile of the 2000 patient cohort was somewhat worse than that of the 1995 cohort in both sex groups, but the distributions of age and left ventricular ejection fraction were similar. Within one year of admission in 2000, 28% of male patients and 27% of female patients have died, compared to 36% and 27% of their counterparts in 1995, respectively. In various Cox regression models the average year effect (2000 as. 1995) was around 0.75 for men and 0.95 to 1.00 for women. The use of angiotensin converting-enzyme inhibitors and beta-blockers was associated with substantially lower hazard of death during the subsequent year. Conclusion: Survival of men who were hospitalized for CHF has improved during the second half of the 1990s. The trend in women was very weak, compatible with little to no change. Documented benefits of angiotensin converting-enzyme inhibitors and beta-blockers were evident in these observational data in both men and women. [ABSTRACT FROM AUTHOR]